Selected research
Market Structure
Global Dry Age-Related Macular Degeneration Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Dry Age-Related Macular Degeneration market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Dry Age-Related Macular Degeneration is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Dry Age-Related Macular Degeneration is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Dry Age-Related Macular Degeneration is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Dry Age-Related Macular Degeneration is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Dry Age-Related Macular Degeneration include Santen Pharmaceuticals, Y2 Solution, Stealth Biotherapeutics, Phio Pharmaceuticals, Ocumension Therapeutics, Kubota Vision, Iveric Bio, Eyestem Research and Belite Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Dry Age-Related Macular Degeneration market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Dry Age-Related Macular Degeneration and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Dry Age-Related Macular Degeneration revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Dry Age-Related Macular Degeneration market size, projected growth trends, production technologies, key applications, and end-use industries.
Dry Age-Related Macular Degeneration Segment by Company
Santen Pharmaceuticals
Y2 Solution
Stealth Biotherapeutics
Phio Pharmaceuticals
Ocumension Therapeutics
Kubota Vision
Iveric Bio
Eyestem Research
Belite Bio
Bausch Health
Allergan
Alimera Science
Dry Age-Related Macular Degeneration Segment by Type
Oral
Injectables
Dry Age-Related Macular Degeneration Segment by Application
Above 40 Years
Above 60 Years
Above 75 Years
Dry Age-Related Macular Degeneration Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dry Age-Related Macular Degeneration market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dry Age-Related Macular Degeneration and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dry Age-Related Macular Degeneration.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Dry Age-Related Macular Degeneration in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dry Age-Related Macular Degeneration industry.
Chapter 3: Detailed analysis of Dry Age-Related Macular Degeneration companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dry Age-Related Macular Degenerationrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injectables
Applications
- Above 40 Years
- Above 60 Years
- Above 75 Years
Companies covered
- Santen Pharmaceuticals
- Y2 Solution
- Stealth Biotherapeutics
- Phio Pharmaceuticals
- Ocumension Therapeutics
- Kubota Vision
- Iveric Bio
- Eyestem Research
- Belite Bio
- Bausch Health
- Allergan
- Alimera Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Dry Age-Related Macular Degeneration Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Injectables
- 1.3 Market Analysis by Application
- 1.3.1 Global Dry Age-Related Macular Degeneration Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Above 40 Years
- 1.3.3 Above 60 Years
- 1.3.4 Above 75 Years
- 1.4 Global Market Growth Prospects
- 1.5 Global Dry Age-Related Macular Degeneration Growth Trends by Region
- 1.5.1 Global Dry Age-Related Macular Degeneration Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Dry Age-Related Macular Degeneration Market Size by Region (2021-2026)
- 1.5.3 Dry Age-Related Macular Degeneration Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Dry Age-Related Macular Degeneration Market Dynamics
- 2.1 Dry Age-Related Macular Degeneration Industry Trends
- 2.2 Dry Age-Related Macular Degeneration Industry Drivers
- 2.3 Dry Age-Related Macular Degeneration Industry Opportunities and Challenges
- 2.4 Dry Age-Related Macular Degeneration Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Dry Age-Related Macular Degeneration Revenue by Company (2021-2026)
- 3.2 Global Dry Age-Related Macular Degeneration Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Dry Age-Related Macular Degeneration Key Company Head office and Area Served
- 3.4 Global Dry Age-Related Macular Degeneration Company, Product Type & Application
- 3.5 Global Dry Age-Related Macular Degeneration Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Dry Age-Related Macular Degeneration Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Dry Age-Related Macular Degeneration Players Market Share by Revenue in 2025
- 3.6.3 2025 Dry Age-Related Macular Degeneration Tier 1, Tier 2, and Tier 3
4 Dry Age-Related Macular Degeneration Market by Type
- 4.1 Global Dry Age-Related Macular Degeneration Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Dry Age-Related Macular Degeneration Market Size by Type (2021-2032)
- 4.3 Global Dry Age-Related Macular Degeneration Market Size Share by Type (2021-2032)
5 Dry Age-Related Macular Degeneration Market by Application
- 5.1 Global Dry Age-Related Macular Degeneration Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Dry Age-Related Macular Degeneration Market Size by Application (2021-2032)
- 5.3 Global Dry Age-Related Macular Degeneration Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Santen Pharmaceuticals
- 6.1.1 Santen Pharmaceuticals Company Information
- 6.1.2 Santen Pharmaceuticals Business Overview
- 6.1.3 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
- 6.1.5 Santen Pharmaceuticals Recent Developments
- 6.2 Y2 Solution
- 6.2.1 Y2 Solution Company Information
- 6.2.2 Y2 Solution Business Overview
- 6.2.3 Y2 Solution Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Y2 Solution Dry Age-Related Macular Degeneration Product Portfolio
- 6.2.5 Y2 Solution Recent Developments
- 6.3 Stealth Biotherapeutics
- 6.3.1 Stealth Biotherapeutics Company Information
- 6.3.2 Stealth Biotherapeutics Business Overview
- 6.3.3 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Product Portfolio
- 6.3.5 Stealth Biotherapeutics Recent Developments
- 6.4 Phio Pharmaceuticals
- 6.4.1 Phio Pharmaceuticals Company Information
- 6.4.2 Phio Pharmaceuticals Business Overview
- 6.4.3 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
- 6.4.5 Phio Pharmaceuticals Recent Developments
- 6.5 Ocumension Therapeutics
- 6.5.1 Ocumension Therapeutics Company Information
- 6.5.2 Ocumension Therapeutics Business Overview
- 6.5.3 Ocumension Therapeutics Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Ocumension Therapeutics Dry Age-Related Macular Degeneration Product Portfolio
- 6.5.5 Ocumension Therapeutics Recent Developments
- 6.6 Kubota Vision
- 6.6.1 Kubota Vision Company Information
- 6.6.2 Kubota Vision Business Overview
- 6.6.3 Kubota Vision Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Kubota Vision Dry Age-Related Macular Degeneration Product Portfolio
- 6.6.5 Kubota Vision Recent Developments
- 6.7 Iveric Bio
- 6.7.1 Iveric Bio Company Information
- 6.7.2 Iveric Bio Business Overview
- 6.7.3 Iveric Bio Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Iveric Bio Dry Age-Related Macular Degeneration Product Portfolio
- 6.7.5 Iveric Bio Recent Developments
- 6.8 Eyestem Research
- 6.8.1 Eyestem Research Company Information
- 6.8.2 Eyestem Research Business Overview
- 6.8.3 Eyestem Research Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Eyestem Research Dry Age-Related Macular Degeneration Product Portfolio
- 6.8.5 Eyestem Research Recent Developments
- 6.9 Belite Bio
- 6.9.1 Belite Bio Company Information
- 6.9.2 Belite Bio Business Overview
- 6.9.3 Belite Bio Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Belite Bio Dry Age-Related Macular Degeneration Product Portfolio
- 6.9.5 Belite Bio Recent Developments
- 6.10 Bausch Health
- 6.10.1 Bausch Health Company Information
- 6.10.2 Bausch Health Business Overview
- 6.10.3 Bausch Health Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Bausch Health Dry Age-Related Macular Degeneration Product Portfolio
- 6.10.5 Bausch Health Recent Developments
- 6.11 Allergan
- 6.11.1 Allergan Company Information
- 6.11.2 Allergan Business Overview
- 6.11.3 Allergan Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Allergan Dry Age-Related Macular Degeneration Product Portfolio
- 6.11.5 Allergan Recent Developments
- 6.12 Alimera Science
- 6.12.1 Alimera Science Company Information
- 6.12.2 Alimera Science Business Overview
- 6.12.3 Alimera Science Dry Age-Related Macular Degeneration Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Alimera Science Dry Age-Related Macular Degeneration Product Portfolio
- 6.12.5 Alimera Science Recent Developments
7 North America
- 7.1 North America Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 7.2 North America Dry Age-Related Macular Degeneration Market Size by Type
- 7.2.1 North America Dry Age-Related Macular Degeneration Market Size by Type (2021-2026)
- 7.2.2 North America Dry Age-Related Macular Degeneration Market Size by Type (2027-2032)
- 7.2.3 North America Dry Age-Related Macular Degeneration Market Share by Type (2021-2032)
- 7.3 North America Dry Age-Related Macular Degeneration Market Size by Application
- 7.3.1 North America Dry Age-Related Macular Degeneration Market Size by Application (2021-2026)
- 7.3.2 North America Dry Age-Related Macular Degeneration Market Size by Application (2027-2032)
- 7.3.3 North America Dry Age-Related Macular Degeneration Market Share by Application (2021-2032)
- 7.4 North America Dry Age-Related Macular Degeneration Market Size by Country
- 7.4.1 North America Dry Age-Related Macular Degeneration Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 7.4.3 North America Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 7.4.4 North America Dry Age-Related Macular Degeneration Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 8.2 Europe Dry Age-Related Macular Degeneration Market Size by Type
- 8.2.1 Europe Dry Age-Related Macular Degeneration Market Size by Type (2021-2026)
- 8.2.2 Europe Dry Age-Related Macular Degeneration Market Size by Type (2027-2032)
- 8.2.3 Europe Dry Age-Related Macular Degeneration Market Share by Type (2021-2032)
- 8.3 Europe Dry Age-Related Macular Degeneration Market Size by Application
- 8.3.1 Europe Dry Age-Related Macular Degeneration Market Size by Application (2021-2026)
- 8.3.2 Europe Dry Age-Related Macular Degeneration Market Size by Application (2027-2032)
- 8.3.3 Europe Dry Age-Related Macular Degeneration Market Share by Application (2021-2032)
- 8.4 Europe Dry Age-Related Macular Degeneration Market Size by Country
- 8.4.1 Europe Dry Age-Related Macular Degeneration Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 8.4.3 Europe Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 8.4.4 Europe Dry Age-Related Macular Degeneration Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 9.2 China Dry Age-Related Macular Degeneration Market Size by Type
- 9.2.1 China Dry Age-Related Macular Degeneration Market Size by Type (2021-2026)
- 9.2.2 China Dry Age-Related Macular Degeneration Market Size by Type (2027-2032)
- 9.2.3 China Dry Age-Related Macular Degeneration Market Share by Type (2021-2032)
- 9.3 China Dry Age-Related Macular Degeneration Market Size by Application
- 9.3.1 China Dry Age-Related Macular Degeneration Market Size by Application (2021-2026)
- 9.3.2 China Dry Age-Related Macular Degeneration Market Size by Application (2027-2032)
- 9.3.3 China Dry Age-Related Macular Degeneration Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 10.2 Asia Dry Age-Related Macular Degeneration Market Size by Type
- 10.2.1 Asia Dry Age-Related Macular Degeneration Market Size by Type (2021-2026)
- 10.2.2 Asia Dry Age-Related Macular Degeneration Market Size by Type (2027-2032)
- 10.2.3 Asia Dry Age-Related Macular Degeneration Market Share by Type (2021-2032)
- 10.3 Asia Dry Age-Related Macular Degeneration Market Size by Application
- 10.3.1 Asia Dry Age-Related Macular Degeneration Market Size by Application (2021-2026)
- 10.3.2 Asia Dry Age-Related Macular Degeneration Market Size by Application (2027-2032)
- 10.3.3 Asia Dry Age-Related Macular Degeneration Market Share by Application (2021-2032)
- 10.4 Asia Dry Age-Related Macular Degeneration Market Size by Country
- 10.4.1 Asia Dry Age-Related Macular Degeneration Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 10.4.3 Asia Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 10.4.4 Asia Dry Age-Related Macular Degeneration Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Type
- 11.2.1 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Application
- 11.3.1 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country
- 11.4.1 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Dry Age-Related Macular Degeneration Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst